WHO预认证部门第10次邀请被忽视热带病药品生产商提交产品评估意向书（EOI），新增Acoziborole 320mg片剂
10th Invitation to Manufacturers of Medicinal Products for Treatment of Neglected Tropical Diseases to Submit an Expression of Interest (EOI) for Product Evaluation to the WHO Prequalification Unit
WHO预认证部门应WHO疟疾与被忽视热带病部门请求，更新第10次被忽视热带病药品生产商产品评估意向书邀请，新增Acoziborole 320mg片剂。该药为口服单剂，用于治疗各期冈比亚人类非洲锥虫病（g-HAT），无需腰椎穿刺确定疾病分期，可避免疗程延长并简化偏远资源有限地区的给药。
News
28 October, 2026 - 00:12 (CET)
Alerts
The Invitation Manufacturers of Medicinal Products for Treatment of Neglected Tropical Disease to Submit an Expression of Interest (EOI) for Product Evaluation to the WHO Prequalification Unit was recently updated following a request by the WHO Malaria and Neglected Tropical Diseases Department.
In particular, the following medicine was added:
- Acoziborole 320mg tablet
Acoziborole is used in the treatment of Human African trypanosomiasis (HAT), a vector-borne parasitic disease, also known as sleeping sickness.
Current therapies for g-HAT involve multiple doses, intravenous infusions or intramuscular injections, as well as hospitalisation. They are selected based on disease stage, which is determined by a lumbar puncture. Acoziborole is an oral, single-dose treatment that is effective in all stages of g-HAT. This regimen removes the need for lumbar puncture to determine disease stage before treatment, avoids a prolonged treatment course and simplifies delivery in remote, resource-constrained settings.
Links
来源：WHO 药品预认证与检查动态 · extranet.who.int